Merck Millipore Launches Lockable ICRplus Settle Plates for Safe and Efficient Viable Air Monitoring and Personnel Monitoring
Merck Millipore, the Life Science division of Merck, has launched lockable ICRplus Settle Plates for viable air monitoring and personnel monitoring in clean rooms and isolators.
The new plates are based on the original Merck Millipore ICR Settle Plate technology and provide semi-quantitative determination of microbial contamination. ICRplus Settle Plates feature a new two-way closure system: the 'CLOSED' position allows safe transportation and aerobic incubation while the 'VENT' position expands incubation for the detection of anaerobic and microaerophilic micro-organisms.
ICRplus Settle Plates are filled with Casein Soybean Digest Agar (TSA), which is recommended by FDA Guidance for Industry (2004): Sterile Drug Products Produced by Aseptic Processing — cGMP. The plates are offered in formulations with neutralizers for the inactivation of disinfectant. In addition, the plates can be used to detect fastidious bacteria when used in combination with Chocolate Agar and lecithin, Tween 80 and histidine (LTH).
“Efficient and reliable environmental monitoring of isolators and clean rooms is essential to support product quality and customer safety,” said Yvonne Hochheimer, Product Manager at Merck Millipore. “With our unique two-way closure system of the ICRplus Settle Plates, customers can be assured of safer transport and reliable detection of aerobic and anaerobic micro-organisms. The plates also offer the ultimate in convenience with room temperature storage at the site of use and a long shelf life. This translates into decreased storage costs and fewer incoming goods controls and QC testing.”
ICRplus Settle Plates are produced under aseptic conditions, gamma-irradiated and triple-bagged, making them optimal for personnel monitoring, passive air sampling and active air sampling with sieve-like samplers (for example, MAS air samplers) in isolators and clean rooms. Furthermore, the new products enable inactivation of residual vaporous hydrogen peroxide (VHP) during active air sampling. Each ICRplus Settle Plate contains a data matrix barcode, which allows secure identification of plates and supports the 'paperless' lab. The 90-mm plates have a high filling volume of 30 mL, which allows prolonged incubation.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance